Neurology SIGNAL-AD

Pepinemak

Support from Alzheimer's Association & Alzheimer's Drug Discovery Foundation

ALZHEIMER'S DISEASE

Data 2H 2024

SIGNAL Pepinemab

HUNTINGTON'S DISEASE

Published, Nature Medicine

Oncology

Pepinemab + Pembrolizumab

KEYNOTE-B84

Partnered with Merck Sharp & Dohme

HEAD AND NECK CANCER

Interim analysis reported 4Q 2023

Pepinemab + Avelumab

NCT03690986

Merck, KGaA Darmstadt, University of Rochester, Gateway Discovery Fdn.

PANCREATIC CANCER

Enrolling

Pepinemab + Avelumab

CLASSICAL-Lung

Partnered with Merck, KGaA Darmstadt

NON SMALL CELL LUNG CANCER

Complete Published

Investigator-sponsored trials

Pepinemab

+ Nivolumab and/or Ipilimumab

NCT03769155

Emory University

with Bristol Myers Squibb

MELANOMA

Enrollment Complete

Pepinemab + Trastuzumab

+ DC Vaccine

NCT05378464

H. Lee Moffitt Cancer Center

BREAST CANCER

Enrolling

Drug Discovery

ActivMAb Technology

VX18

Neurology Inflammation

CXCR5 Mab

Oncology Inflammation

Available for licensing

CXCL13 Mab

Available for licensing

Inflammation

ActivMab®

Maximizing success to find Ab therapeutics for difficult-to-drug targets

Antibody Drug Discovery

Antigen Virus Particles

m

CUSTOM PROJECTS

Multiple pharma and biotech

CONTACT US for custom projects!

View our catalog on Science Exchange